在有有 adefovir dipivoxil 的 lamivudine 抵抗的肝炎 B 肝硬化的一个病人的 HCC 的外科的治疗

• 作者: Hidetsugu Yamagishi Hideyuki Hiraishi Keiichi Kubota Masaya Tamano Takahiro Fujimori Takashi Akima
• 来源期刊: 世界肝病学杂志：英文版（电子版）
• 学科: 医学
• 关键词: HEPATITIS B virus HEPATOCELLULAR carcinoma HEPATOCARCINOGENESIS LAMIVUDINE ADEFOVIR dipivoxil
• 年，卷（期）: 2010,（8）
• 页码范围: 318-321
• 页数: 4页
• 分类号: R735.7

摘要

We describe a 77-year-old woman with chronic hepatitis B who became resistant to lamivudine.She was started on adefovir(10 mg daily)while still continuing lamivudine therapy.Four mo later her liver function improved and serum Hepatitis B virus(HBV)-DNA level became undetectable.Three years after the start of additional adefovir treatment,hepatocellular carcinoma (HCC)was detected and the patient underwent a successful hepa-tectomy.Our findings suggest tha-t the addition of adefovir to ongoing lamivudine therapy cannot completely suppress hepatocarcinogenesis,but is useful for improving liver function in patients with lamivudine-resistant HBV-related cirrhosis,allowing HCC surgery.